Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yokoyama, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yokoyama, T.
(Chest. 1972;62:191-198.)
© 1972 American College of Chest Physicians

Diagnostic Significance of Arterial-Alveolar Nitrogen Tension Difference in Assessment of Ventilation-Perfusion Ratio Inequality

Tetsuro Yokoyama M.D., F.C.C.P.1

1 Assistant Professor of Medicine, School of Medicine, Keio University, Tokyo, Japan

Arterial-alveolar N2 tension difference (aADN2) was studied as a measure to assess ventilation-perfusion ratio uneveness in the lungs in 186 healthy subjects, 37 patients with manifested asthma, 28 with chronic pulmonary emphysema and 36 with bronchitis. The healthy subjects exhibited a different distribution pattern in incidence of aADN2 with regard to their age groups. The mean, standard deviation, and 95 percent upper confidence limit for young healthy adults was 3.3 mmHg, 2.4 mmHg, 8.1 mmHg, respectively. Those for healthy aged persons were 5.6 mmHg, 3.3 mmHg, 12.2 mmHg, respectively. The author proposed aADN2 of 8.0 mmHg as the upper diagnostic limit for young adults 40 years of age or younger, 12.0 mmHg for healthy persons aged more than 40 years. If the subject's age was not considered, 10.0 mmHg was the proposed upper diagnostic limit. aADN2 of patients with manifested asthma, chronic pulmonary emphysema, and bronchitis showed a tendency to increase more than the proposed upper diagnostic limit. aADN2 for some bronchitic and asthmatic patients was increased, even though their FEV1.0 percent remained within normal limits. aADN2 Obtained in patients with manifested asthma decreased after bronchodilator aerosol inhalation. Changes in aADN2 after administration of a bronchodilator did not reveal a statistically consistent correlation between FEV1.0 percent and FMF. aADN2 was increased in patients with depressed Co pulmonary diffusing capacity. aADN2, in general, was inversely correlated with the breathholding CO pulmonary diffusing capacity.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1972 by the American College of Chest Physicians.